CAITLIN STORK: Open Payments
NPI 1275254542 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,023 in 122 payments from 23 companies in 2025. Trend: 2023 $3,327 · 2024 $2,754 · 2025 $2,023
Food & beverage: $2,023
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $328 |
| ABBVIE INC. | 19 | $301 |
| Lilly USA, LLC | 12 | $257 |
| AstraZeneca Pharmaceuticals LP | 10 | $219 |
| Amgen Inc. | 25 | $188 |
| Xeris Pharmaceuticals, Inc. | 5 | $93 |
| Dexcom, Inc. | 4 | $90 |
| GlaxoSmithKline, LLC. | 5 | $80 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $75 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $59 |
Products named: VRAYLAR, MOUNJARO, Ozempic, OTEZLA, FARXIGA, AIRSUPRA, Wegovy, GVOKE HYPOPEN.
Industry payments across TX — which companies pay providers there.
